Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.56B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 1.86M
Average 3.08M
SRPT Account Payables
Amounts the company owes suppliers for goods and services received.
Sarepta Therapeutics, Inc.NASDAQ: SRPT
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 54.9% from a year ago
Account payables stood at $70.38M at the end of Q1 FY2026, down 54.9% from a year earlier and down 74.9% from the prior quarter. Over 3 fiscal years it compounded at +43.1% a year.
Context
- Account payables amounted to 2.2% of total assets at the end of Q1 FY2026, down 2.3 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -54.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 280.84M USD
- Year-over-year change
- +31.0%
- 4-year CAGR
- +38.3%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 280.84M | +31.0% |
| FY2024 | 2024-12-31 | 214.44M | +30.0% |
| FY2023 | 2023-12-31 | 164.92M | +72.0% |
| FY2022 | 2022-12-31 | 95.88M | +24.9% |
| FY2021 | 2021-12-31 | 76.74M | — |
Account Payables vs competitors
How SRPT compares with its peers on the latest reported figures
- SRPT's Mar 2026 account payables of $70.38M is the 2nd highest of the 11 companies compared; the peer median is $15.48M.
- Its year-over-year change of -54.9% is the 10th highest of 11, against a peer median of -3.9%.
- Account payables amounts to 2.2% of total assets for SRPT, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $108.02M | +5.5% | +5.7% | 1.9% | |
| Mar 2026 | $70.38M | -54.9% | +43.1% | 2.2% | |
| Jun 2026 | $40.45M | +52.6% | +18.6% | 1.2% | |
| Sep 2026 | $27.11M | +89.3% | +16.2% | 0.9% | |
| Mar 2026 | $19.06M | +32.8% | -2.5% | 3.3% | |
| Mar 2026 | $18.8M | +52.1% | +57.8% | 2.5% | |
| Jun 2026 | $12.15M | -13.3% | +15.4% | 1.2% | |
| Mar 2026 | $5.56M | -13.6% | -0.1% | 1.3% | |
| Mar 2026 | $3.93M | -25.2% | -30.0% | 1.2% | |
| Mar 2026 | $2.28M | -28.4% | -8.6% | 1.0% | |
| Mar 2026 | $622K | -77.0% | -15.5% | 0.4% | |
| Peer median (excluding SRPT) | $15.48M | -3.9% | +2.8% | 1.2% | |
Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.12B | 966.78M | 428.43M | 1.1B | 801.28M |
| Short-term Investments | 0 | 1.02B | 1.25B | 251.78M | 138.37M |
| Net Receivables | 172.75M | 261.6M | 436.98M | 649.73M | 519.61M |
| Inventory | 186.21M | 203.97M | 322.86M | 749.96M | 914.74M |
| Other Current Assets | 5.3M | 6.82M | 12.48M | 9.21M | 9.2M |
| Total Current Assets | 2.6B | 2.56B | 2.58B | 3.07B | 2.54B |
| Property, Plant & Equipment (Net) | 236.69M | 244.99M | 357.11M | 488.65M | 470.62M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 14.24M | 7.58M | 29.62M | 26.89M | 28.95M |
| Long-term Investments | 34.89M | 31.32M | 6.53M | 136.87M | 1.05M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 258.06M | 286.62M | 291.99M | 237.3M | 311.15M |
| Total Non-current Assets | 543.88M | 570.51M | 685.25M | 889.71M | 811.77M |
| Total Assets | 3.15B | 3.13B | 3.26B | 3.96B | 3.35B |
| Account Payables | 76.74M | 95.88M | 164.92M | 214.44M | 280.84M |
| Short-term Debt | 0 | 0 | 105.48M | 0 | 0 |
| Tax Payables | 216K | 12.52M | 13.77M | 17.39M | 0 |
| Deferred Revenue | 89.24M | 89.24M | 50.42M | 130.26M | 443.4M |
| Other Current Liabilities | 110.44M | 134.73M | 178.81M | 200.28M | 176.13M |
| Total Current Liabilities | 452.73M | 619.6M | 653.66M | 731.68M | 1.1B |
| Long-term Debt | 1.1B | 1.54B | 1.13B | 1.14B | 828.97M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 574.24M | 485M | 437M | 325M | 83.91M |
| Other Non-current Liabilities | 54.6M | 36.94M | 41.1M | 49.15M | 1.53M |
| Total Non-current Liabilities | 1.77B | 2.12B | 1.75B | 1.7B | 1.11B |
| Total Liabilities | 2.22B | 2.74B | 2.41B | 2.44B | 2.21B |
| Common Stock | 9K | 9K | 9K | 10K | 11K |
| Retained Earnings | (3.21B) | (3.91B) | (4.45B) | (4.21B) | (4.88B) |
| Accumulated OCI | (20K) | (1.66M) | 918K | (218K) | 272K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 928.01M | 384.95M | 859.34M | 1.53B | 1.14B |
| Total Debt | 1.15B | 1.62B | 1.4B | 1.34B | 1.04B |
| Net Debt | (962.43M) | 650.58M | 968.38M | 240.06M | 238.46M |
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
Intrinsic Alpha fair value
Locked
Current Price
$14.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.